Leal, formerly known as Trialjectory, has established a predictive patient platform that offers to 1) help cancer patients navigate their treatment journey at all stages of the disease, 2) educate patients and their oncologists about all of their treatment options in a timely manner to remove barriers to care in advance and 3) enable the pharmaceutical industry to identify potential patients that could match to their trials in the future.
Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report.
